Early Menarche May Add to Risk of ER− Breast CA in Black Women

This article originally appeared here.
Share this content:
Early Menarche May Add to Risk of ER− Breast CA in Black Women
Early Menarche May Add to Risk of ER− Breast CA in Black Women

TUESDAY, Aug. 18, 2015 (HealthDay News) -- Age at menarche could play a role in development of estrogen receptor-negative (ER−) breast cancers among African-American women, according to a study published in the September issue of the Journal of the National Cancer Institute.

Christine B. Ambrosone, Ph.D., from the Roswell Park Cancer Institute in Buffalo, N.Y., and colleagues analyzed data gathered from the AMBER Consortium (4,426 African-American women with breast cancer and 17,474 controls). The authors performed polytomous logistic regression to estimate odds ratios (ORs) for ages at menarche and first live birth (FLB), and the interval between, in relation to ER+ and ER− breast cancer.

The researchers found that risk of ER− breast cancer was reduced with later age at menarche among both parous and nulliparous women (≥15 versus <11 years; ORs, 0.62 [95 percent confidence interval, 0.48 to 0.81] and 0.56 [95 percent confidence interval, 0.29 to 1.10], respectively), with no effect of age at FLB. The inverse association was weaker among nulliparous women with ER+ breast cancer. Longer intervals between menarche and FLB were associated with increased risk of ER+ breast cancer in a dose-response manner (OR for 20 year interval, 1.39; Ptrend = 0.003); however, ER− risk was only increased for intervals up to 14 years (Ptrend = 0.33).

"These findings indicate that etiologic pathways involving adolescence and pregnancy may differ for ER− and ER+ breast cancer," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

WHO: Vaccine Hesitancy a Major Global Health Threat

WHO: Vaccine Hesitancy a Major Global Health Threat

Percentage of U.S. children 19 to 35 months who have not been vaccinated has quadrupled since 2001

FDA Down to 5 Weeks of Funding to Review New Drug Applications

FDA Down to 5 Weeks of Funding to ...

Agency cannot accept new fees or applications until the shutdown is over

FDA Approves First Generic Version of Epilepsy Drug Sabril

FDA Approves First Generic Version of Epilepsy Drug ...

Generic equivalents held to same vigorous manufacturing standards as brand-name drugs

is free, fast, and customized just for you!




Already a member?

Sign In Now »